Belabbas et al. 2023
Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance
Journal of Infection and Chemotherapy · 10.1016/j.jiac.2023.01.010
Structure
A one-compartment model, driven by weight, creatinine clearance and neutropenia.
Study population
Hematologic malignancy and Neutropenia patients — Japan and Asia. Fitted to 148 patients and 681 concentration observations.
| Covariate | As reported |
|---|---|
| Age | 59 (20–82) yr |
| Weight | 57.9 (34.4–105) kg |
| BMI | 21.4 (14.4–33.6) kg/m² |
| CrCl | 112 (12.9–324) mL/min |
| SCr | 0.58 (0.2–5.2) mg/dL |
Reported as the source publication gives them — mean ± SD, or median with range or interquartile range.
Equations
The model's structural parameters as Chorus implements them.
LaTeX source
CL = 3.09 \cdot \left(\frac{CrCl}{90}\right)^{0.973} \cdot 1.07^{Neut} \quad (CrCl < 130)
CL = 3.09 \cdot \left(\frac{CrCl}{90}\right)^{0.973} \cdot 1.13^{Neut} \quad (CrCl \geq 130)
V_1 = 122 \cdot \frac{Weight}{70}
Implementation notes
Final ARC-stratified model (eq. 2). Neutropenia multiplies clearance by 1.07 when CrCl < 130 mL/min and by 1.13 when CrCl ≥ 130 mL/min (the augmented-renal-clearance threshold), driven by the patient's neutropenia tag. The AML covariate (×1.15) is omitted: the calculator does not collect an AML-specific tag, and the broader hematologic-malignancy tag is intentionally not used for it to avoid over-applying the AML-specific clearance increase to non-AML patients.